Clinical trial NCT02280096 - References

Multiple Sclerosis — Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

Citation(s)

•   Amato MP, Portaccio E, Zipoli V
  Are there protective treatments for cognitive decline in MS? J Neurol Sci. 2006 Jun 15;245(1-2):183-6. Epub 2006 Apr 27. Review.
•   Romani A, Bergamaschi R, Candeloro E, Alfonsi E, Callieco R, Cosi V
  Fatigue in multiple sclerosis: multidimensional assessment and response to symptomatic treatment. Mult Scler. 2004 Aug;10(4):462-8.
•   Rossini PM, Pasqualetti P, Pozzilli C, Grasso MG, Millefiorini E, Graceffa A, Carlesimo GA, Zibellini G, Caltagirone C
  Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine. Mult Scler. 2001 Dec;7(6):354-8.
•   Ruck T, Bittner S, Simon OJ, Göbel K, Wiendl H, Schilling M, Meuth SG
  Long-term effects of dalfampridine in patients with multiple sclerosis. J Neurol Sci. 2014 Feb 15;337(1-2):18-24. doi: 10.1016/j.jns.2013.11.011. Epub 2013 Nov 16.
•   Smits RC, Emmen HH, Bertelsmann FW, Kulig BM, van Loenen AC, Polman CH
  The effects of 4-aminopyridine on cognitive function in patients with multiple sclerosis: a pilot study. Neurology. 1994 Sep;44(9):1701-5.

Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis. Randomized, Blinded, Placebo-controlled Clinical Trial.

Details for clinical trial NCT02280096